Pain scale

The Pankey Institute Announces the 2022 Recipients of its Lifelong Impact Awards

Retrieved on: 
Wednesday, December 14, 2022
Faculty, Dentistry, Sacroiliac joint, Milken Educator Award, Female, Life, Patient, Curriculum, DDS, Live Legacy, Knowledge, KEY, Pain scale, Face, TMD, Practice management, Orofacial pain, Dentist, Medical device, Education

KEY BISCAYNE, Fla., Dec. 14, 2022 /PRNewswire/ -- "The Living Legacy Award and the Excellence in Education Award recognize members of the dental community who have made a significant lifelong impact," explained Dr. Lee Ann Brady, Executive Director.

Key Points: 
  • The Pankey Institute announced the recipients of its 2022 Living Legacy and Excellence in Education awards at their annual Symposium meeting.
  • KEY BISCAYNE, Fla., Dec. 14, 2022 /PRNewswire/ -- "The Living Legacy Award and the Excellence in Education Award recognize members of the dental community who have made a significant lifelong impact," explained Dr. Lee Ann Brady, Executive Director.
  • The Living Legacy Award is given each year to a member of the Pankey community who has shown exemplary support of the Pankey Philosophy while carrying out the mission and vision of the Pankey Foundation.
  • The 2022 Living Legacy Award was presented to Yvonne S. Hanley, DDS of Fergus Falls, MN.

Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit

Retrieved on: 
Thursday, December 1, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, COVID-19, Inflammasome, Pain scale, Therapy, Neurology, NLRP3, Protein, Resolve, Inflammation, CNS, Pyroptosis, Multiple sclerosis, Pharmacology, Health, Rheumatism, Pharmaceutical industry, Vitro

She also provided an update on the companys brain-penetrant NLRP3 inhibitor, VENT-02, which was recently selected as Ventus second development candidate.

Key Points: 
  • She also provided an update on the companys brain-penetrant NLRP3 inhibitor, VENT-02, which was recently selected as Ventus second development candidate.
  • As Ventus second NLRP3 development candidate, it shows our belief in targeting this inflammasome to address systemic and neurological diseases, said Ms. Auger.
  • NLRP3 is a member of a family of proteins known as inflammasome receptors and is integral in the formation of the NLRP3 inflammasome.
  • Therapeutic inhibition of NLRP3 can, therefore, prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1 and IL-18.

NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Growth, Epilepsy, Evo, Electrode, NMTC, Multimedia, Risk, Partnership, Brain, EDEN, Chronic pain, Patient, Hyperreflexia, Seeg, DBS, Parkinson's disease, Pain scale, EEG, Dystonia, Security (finance), Noise, Deep brain stimulation, Clinical trial, FDA, Skull, Medical device

EDEN PRAIRIE, Minn., Nov. 30, 2022 /PRNewswire/ --  NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it shipped the first commercial order to Zimmer Biomet for its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.  Zimmer Biomet is the exclusive worldwide distribution partner for the NeuroOne Evo Cortical and sEEG electrode product lines.

Key Points: 
  • Zimmer Biomet is the exclusive worldwide distribution partner for the NeuroOne Evo Cortical and sEEG electrode product lines.
  • We look forward to commercialization of this exciting technology in the future in partnership with Zimmer Biomet
    The Evo sEEG System represents the Company's second FDA 510(k) cleared product.
  • sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.
  • The Company's Evo Cortical and sEEG Electrodes are a portfolio of hi-definition thin film electrodes.

SOUTH FLORIDA PBS LAUNCHES HEALTH CHANNEL ON FAST CHANNELS TV

Retrieved on: 
Tuesday, November 15, 2022
Marketing, Mahendra Sukhdeo, Nutritionist, VOD, Gastroesophageal reflux disease, Health, University, Channel, Partnership, Nursing, IBS, Feinberg School of Medicine, FAST, University School, Human, PBS, South Florida PBS, Prostate cancer, Duke University, Discovery Health Channel, Q & A, Channels TV, Pain scale

Miami, Florida, Nov. 15, 2022 (GLOBE NEWSWIRE) -- MIAMI, FL South Florida PBS Health Channel has partnered with FAST Channels TV, a premium video platform, to deliver a new FAST channel which will include a line-up of Health Channel original productions:

Key Points: 
  • Miami, Florida, Nov. 15, 2022 (GLOBE NEWSWIRE) -- MIAMI, FL South Florida PBS Health Channel has partnered with FAST Channels TV, a premium video platform, to deliver a new FAST channel which will include a line-up of Health Channel original productions:
    Health Insiders - Digging deep into reliable medical information, viewers can expect gripping patient stories and actionable advice from doctors, specialists, nurses, nutritionists, and fitness specialists.
  • On partnering with FAST Channels TV, Dolores (Sukhdeo) Alonso Fernandez, South Florida PBS President & CEO, stated: By distributing our content via FAST Channels TV and reaching a wider audience, we are hopeful that the Health Channel will inspire, inform, and encourage viewers to live a healthier life.
  • Russell Foy, CEO of Fast Channels TV, commented: The addition of South Florida PBS' Health Channel to FAST Channels TVs diverse content catalog further demonstrates our commitment to expand and deliver top-tier entertainment, opening up new opportunities for customers to get their content in front of global audiences.
  • FAST Channels TV specializes in content and monetization behind FAST Server-Side Ad Insertion (SSAI) linear Channels and VOD.

CDAHK Chiropractors Pushes Healthy Feeding of Children

Retrieved on: 
Saturday, November 26, 2022
Tao, CRP, NP-hardness, Gingivitis, SIRVA, Bell's palsy, Pain scale, Calisto occulta, Case report, Patient, Metastasis, Diarrhea, Breast milk, Interview, Academy of Family Physicians of India, Foramen magnum, Dizziness, Parkinson's disease, Breast cancer, UNICEF, Health, Deformity, Prostate cancer, Vaccination, COVID-19, Growth, Postural orthostatic tachycardia syndrome, Food, Parent, Literature review, Life, Medical Science Monitor, Low back pain, Research, Pectus carinatum, Global Health, PubMed Central, Multimedia, Mother, Neck pain, Vertebral hemangioma, Pathology, Prevalence, Death, Headache, Streptococcus oralis, Signs and symptoms, PubMed, Abdominal aortic aneurysm, Toy, Birth control, Dietary supplement, Poultry, Renewable energy, Medical device, Online shopping, Chiropractic

LOS ANGELES, Nov. 26, 2022 /PRNewswire/ -- A study in the journal BMJ Global Health found that mothers who were exposed to a lot of digital marketing were less likely to breastfeed their babies for the first six months of their lives and more likely to give them processed foods and sugary drinks.

Key Points: 
  • Chiropractors from the CDAHK say that for your baby's best growth, development, and health, you should only breastfeed him or her for the first six months of life.
  • He received the prestige Effective Outreach Partner Award for the contribution to breastfeeding by the United Nation Children Foundation (UNICEF).
  • The CDAHK's vision and actions always aim at forging business and educating the public about healthy feeding enduring meaning and value that will eventually shape an exceptional future.
  • This call to action is very important to protect children's health and their right to breast milk and natural, healthy, enough, and good food.

Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference

Retrieved on: 
Monday, November 21, 2022
Fitness & Nutrition, Health, Other Health, Patient, GLS, FDA, Wolfe, Body mass index, Defecation, Absorption, Exercise, Food, Abdomen, Citric acid, Flatulence, Non-alcoholic fatty liver disease, Pain scale, NASH, Use, Allergy, BMI, Conference, Multimedia, NYSE, Type 2 diabetes, Obesity, Functional constipation, Diet, Gel, Cellulose, Security (finance), Pharming, Nature, NAFLD, Gelatin, Annual report, Chief commercial officer, Human, Diarrhea, Incidence, Dietary supplement, Risk management, Hydrogel

Gelesis Holdings, Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Researchs virtual Consumer Growth Conference.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Researchs virtual Consumer Growth Conference.
  • View the full release here: https://www.businesswire.com/news/home/20221121005103/en/
    Plenity is inspired by nature and FDA cleared to aid in weight management.
  • (Photo: Business Wire)
    To listen to the live event or to schedule a meeting, please contact your Wolfe representative.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

Retrieved on: 
Wednesday, November 16, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, FDA, National Organization for Rare Disorders, Nervous system, Ophthalmology, Brain, Investment, Biotechnology, Entrepreneurship, Therapy, Hyperkinesia, Drug development, Epilepsy, Trigeminal neuralgia, Howard Hughes Medical Institute, Multimedia, Conditional sentence, NORD, Triangle Park (Quezon City), Death, Acquisition, Disease, Central nervous system, Neuron, Neurological disorder, Ion, Neurology, SUDEP, Silicon, Pain scale, Patient, Pharmaceutical industry, Kriyā

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
  • The acquisition serves as the foundation for Kriyas neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
  • Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy.
  • The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in metabolic disorders, neurology and ophthalmology.

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

Retrieved on: 
Wednesday, November 16, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Janus, GC, Janus Henderson, GlaxoSmithKline, Infection, Serie A1 (water polo), Vaccine, PLC, CDC, Doctor of Philosophy, RA, EC, Pain scale, Shingles, Patient, Pharmaceutical industry, Ćurevo

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.

Key Points: 
  • Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
  • We see significant commercial potential for a shingles vaccine that could match the clinical profile of Shingrix (currently annualizing at $3B in sales) without manufacturing capacity constraints.
  • As Curevo's oldest partner, we are proud to continue to support accessible vaccines to prevent shingles, stated EC Huh, PhD, GC Biopharmas President.
  • Its lead product is CRV-101, a sub-unit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

Retrieved on: 
Wednesday, November 23, 2022
Observation, IX, Lightheadedness, Swelling, Pediatrics, Factor IX, Joint, Nausea, Pain scale, Rash, Iron deficiency, Hepatocellular carcinoma, University, Research, Muscle, CSL Behring, Patient, Incidence, Blood, Caregiver, CSL, Death, Pain, Haemophilia B, Pyelonephritis, Vaccine, Pathology, Haemophilia, AAV, Bleeding, Headache, Semen, Shivering, Safety, Liver cancer, ASX, Disease, Risk, Research and development, Nephrology, Abdominal pain, Padua, ABR, Cell, Cardiogenic shock, Immunodeficiency, Professor, Food, Development, Tissue, Clinical trial, Flushing, Freedom, Dialysis, Biotechnology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transplant, FDA, Lance, Liver, Coalition, Fatigue, R, Medical device, Pharmaceutical industry, Dietary supplement

KING OF PRUSSIA, Pa., Nov. 22, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes. In the ongoing clinical trial, HEMGENIX reduced the rate of annual bleeds and 94 percent of patients discontinued factor IX prophylaxis and remained prophylaxis-free.

Key Points: 
  • "We are thrilled to witness this milestone in hemophilia B treatment," shared Kim Phelan, Chief Operating Officer of The Coalition for Hemophilia B.
  • The FDA approval is supported by results from the ongoing HOPE-B trial, the largest gene therapy trial in hemophilia B to date.
  • CSL Behring, a CSL business, will make HEMGENIX available for eligible people with hemophilia B as soon as possible.
  • HEMGENIX is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B.

Chiropractic May Offer Relief From Complicated Chronic Headaches

Retrieved on: 
Monday, November 21, 2022
Tao, Signs and symptoms, Report, Postural orthostatic tachycardia syndrome, Pathology, Sensation, Neck, Neck pain, Pectus carinatum, Neurofibromatosis, Chronic pain, Pain scale, Lactic acid, History, Chiropractic, Foramen magnum, Spine, ECP, Multimedia, Dizziness, Patient, Head, Executive Committee, Bell's palsy, Radiculopathy, Academy of Family Physicians of India, Literature review, CRP, Dentistry, Poultry, Birth control, Healthcare, Online shopping, Headache

NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.

Key Points: 
  • The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.
  • Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong.
  • "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches.
  • Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.